{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:27Z","timestamp":1788957387549,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sphingosine-1-phosphate receptor modulators and anti-CD20 treatment are widely used disease-modifying treatments for multiple sclerosis. Unfortunately, they may impair the patient\u2019s ability to mount sufficient humoral and T-cellular responses to vaccination, which is of special relevance in the context of the SARS-CoV-2 pandemic. We present here a case series of six multiple sclerosis patients on treatment with sphingosine-1-phosphate receptor modulators who failed to develop SARS-CoV-2-specific antibodies and T-cells after three doses of vaccination. Due to their ongoing immunotherapy, lacking vaccination response, and additional risk factors, we offered them pre-exposure prophylactic treatment with monoclonal SARS-CoV-2-neutralizing antibodies. Initially, treatment was conducted with the antibody cocktail casirivimab\/imdevimab. When the SARS-CoV-2 Omicron variant became predominant, we switched treatment to monoclonal antibody sotrovimab due to its sustained neutralizing ability also against the Omicron strain. Since sotrovimab was approved only for the treatment of COVID-19 infection and not for pre-exposure prophylaxis, we switched treatment to tixagevimab\/cilgavimab as soon as it was granted marketing authorization in the European Union. This antibody cocktail has retained, albeit reduced, neutralizing activity against the Omicron variant and is approved for pre-exposure prophylaxis. No severe adverse events were recorded for our patients. One patient had a positive RT-PCR for SARS-CoV-2 under treatment with sotrovimab, but was asymptomatic. The other five patients did not develop symptoms of an upper respiratory tract infection or evidence of a SARS-CoV-2 infection during the time of treatment up until the finalization of this report. SARS-CoV-2-neutralizing antibody treatment should be considered individually for multiple sclerosis patients lacking adequate vaccination responses on account of their immunomodulatory treatment, especially in times of high incidences of SARS-CoV-2 infection.<\/jats:p>","DOI":"10.3389\/fimmu.2022.897748","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T08:58:23Z","timestamp":1658825903000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses"],"prefix":"10.3389","volume":"13","author":[{"given":"Christina","family":"Woopen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Konofalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000013108","article-title":"Humoral- and T-Cell\u2013specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies","volume":"98","author":"Tortorella","year":"2022","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701752","article-title":"Approach to SARS-CoV-2 vaccination in patients with multiple sclerosis","volume":"12","author":"Woopen","year":"2021","journal-title":"Front Immunol"},{"key":"B3","unstructured":"MalinJ\n            SpinnerC\n            F\u00e4tkenheuerG\n            SalzbergerB\n            KlugeS\n            Karagiannidis\n          SARS-CoV-2 pr\u00e4-expositionsprophylaxe (PrEP) mit neutralisierenden monoklonalen antik\u00f6rpern: Neue m\u00f6glichkeiten f\u00fcr risikogruppen durch passive immunisierung2021"},{"key":"B4","unstructured":"Union register of medicinal products for human use2021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"NEJMoa2108163","DOI":"10.1056\/nejmoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"NEJMoa2035002","DOI":"10.1056\/nejmoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2020","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection","volume":"327","author":"O\u2019Brien","year":"2022","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","first-page":"NEJMoa2109682","DOI":"10.1056\/nejmoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.06.045","article-title":"Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19","author":"Isa","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21268048","article-title":"Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles","volume":"2021","author":"Syed","year":"2022","journal-title":"Medrxiv"},{"key":"B12","unstructured":"Union register of medicinal products for human use2021"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00751-9","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","author":"Self","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"New Engl J Med"},{"key":"B18","unstructured":"Union register of medicinal products for human use2022"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac143","article-title":"Omicron variant escapes therapeutic monoclonal antibodies (mAbs) including recently released evusheld\u00ae, contrary to 8 prior main variant of concern (VOC)","author":"Boschi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/s41598-022-08559-5","article-title":"In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 omicron B.1.1.529 isolate","volume":"12","author":"Touret","year":"2022","journal-title":"Sci Rep-uk"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103944","article-title":"Increased resistance of SARS-CoV-2 omicron variant to neutralization by vaccine-elicited and therapeutic antibodies","volume":"78","author":"Tada","year":"2022","journal-title":"Ebiomedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.05.008","article-title":"Pre-exposure prophylaxis with 300 mg EvusheldTM elicits limited neutralizing activity against the omicron variant","author":"Benotmane","year":"2022","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00436-4","article-title":"Not just antibodies: B cells and T cells mediate immunity to COVID-19","volume":"20","author":"Cox","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00804-1","article-title":"COVID-19 in patients with multiple sclerosis: Associations with disease-modifying therapies","volume":"35","author":"Reder","year":"2021","journal-title":"CNS Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1092","DOI":"10.1212\/nxi.0000000000001092","article-title":"COVID-19 infection in fingolimod- or siponimod-treated patients: Case series","volume":"9","author":"Sullivan","year":"2022","journal-title":"Neurol  Neuroimmunol Neuroinflamm"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103735","article-title":"Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies","volume":"60","author":"Smith","year":"2022","journal-title":"Mult Scler Relat Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.897748\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T08:58:26Z","timestamp":1658825906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.897748\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2022.897748"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.897748","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"article-number":"897748"}}